JILLIAN TOAL: Open Payments
NPI 1619408358 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$561 in 32 payments from 11 companies in 2025. Trend: 2023 $36 · 2024 $27 · 2025 $561
Food & beverage: $561
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $135 |
| Regeneron Healthcare Solutions, Inc. | 6 | $115 |
| Lilly USA, LLC | 3 | $62 |
| Janssen Biotech, Inc. | 3 | $61 |
| Ardelyx, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Gilead Sciences, Inc. | 1 | $15 |
Products named: DUPIXENT, RINVOQ, OMVOH, TREMFYA, IBSRELA, XIFAXAN, VOQUEZNA, LINZESS.
Industry payments across PA — which companies pay providers there.
